Skip to content
OpenCapital
Get started

Organon OGN Proscar — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Pfizer logo
PFEProduct — Revenue
$11.72B+3.7%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
Bristol-Myers Squibb logo
BMYSprycel — Total Revenues
$73M-58.3%
Eli Lilly logo
LLYNet product revenue — Revenue
$18.45B+59.1%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's proscar — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's proscar — revenue?
Organon (OGN) reported proscar — revenue of $26M in Q1 2026.
How has Organon's proscar — revenue changed year-over-year?
Organon's proscar — revenue increased by 8.3% year-over-year, from $24M to $26M.
What is the long-term trend for Organon's proscar — revenue?
Over 4 years (2021 to 2025), Organon's proscar — revenue has grown at a -4.4% compound annual growth rate (CAGR), from $116M to $97M.
What does proscar — revenue mean?
This metric represents the total net sales generated from the Proscar product line within the established medicines portfolio. It reflects the market demand and revenue contribution of this specific pharmaceutical therapy, serving as an indicator of the product's lifecycle stage and its role in the company's broader revenue mix. Monitoring this figure helps investors assess the stability and performance of legacy assets within the company's established brands segment.